Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

lachlan conference
September 3rd, 2024

What's Next for Clinuvel Pharmaceuticals?

Over the last seven years, Clinuvel Pharmaceuticals (CUV: $14.95) has generated around $330 million in sales from its pharmaceutical product Scenesse for the treatment of EPP. The compound annual growth rate in sales over the last six years has been 42% and the company has been profitable for the last seven years.

CUV Parkinsons
July 10th, 2024

Clinuvel Pharmaceuticals Continues Expansion of Portfolio into Parkinson's Disease

Clinuvel Pharmaceuticals (CUV: $15.51) is continuing to expand the applications for its core therapeutic, afamelanotide (Scenesse for the treatment of EPP). In preclinical models it has been shown that afamelanotide can have a positive impact on neurological conditions, including Parkinson's disease.

CLINUVEL ONETIME USE
December 12th, 2023

Investor Interest Starts Return to Biotech Sector (Clinuvel)

Over the last two months, there have been some strong price movements in several major and minor biotech stocks. Following a downturn that has lasted almost two years, has the Australian sector finally bottomed?

We reviewed Clinuvel Pharmaceuticals, Dimerix, Imugene, and Neuren.

 

CUV1
November 20th, 2023

Clinuvel Pharmaceuticals - Core Growth Focus Ahead

Clinuvel Pharmaceuticals (CUV: $16.62) has built a profitable business from the successful commercialization of Scenesse, a drug indicated for the treatment of EPP (erythropoietic protoporphyria). In the last financial year, revenue was up 19% and net profit was up 46% to $30.6 million. The company finished June with a cash balance of $157 million.

CUV 943
September 19th, 2023

Clinuvel Pharmaceuticals v. Nanosonics

Two highly successful life science companies that have emerged in the last decade in Australia are Clinuvel Pharmaceuticals (CUV: $15.64) and Nanosonics (NAN: $4.37). Whilst one is a pharmaceutical company and the other sells medical products (the Trophon disinfection instrument for ultrasound probes), there are several commonalities between the two businesses which make a comparison worthwhile.

CUV 944
September 4th, 2023

Robust Growth Expected to Continue for Clinuvel Pharmaceuticals

For FY2023, Clinuvel Pharmaceuticals (CUV: $18.15) achieved total revenues of $83 million, which was up 24% on the previous year. The net profit for the year increased by 47% to $30.6 million. The company finished the year with $157 million in cash.

Pages